293 related articles for article (PubMed ID: 37148355)
21. Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
Pirisino R; Filippi L; D'Agostini A; Bagni O
Clin Nucl Med; 2022 Nov; 47(11):e692-e695. PubMed ID: 35695716
[TBL] [Abstract][Full Text] [Related]
22. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
23. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
Wong KK; Frey KA; Niedbala J; Kaza RK; Worden FP; Fitzpatrick KJ; Dewaraja YK
Nucl Med Commun; 2022 Aug; 43(8):892-900. PubMed ID: 35703269
[TBL] [Abstract][Full Text] [Related]
24. The inferior performance of [
Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions.
Ensign SF; Agarwal M; Klanderman M; Badawy M; Halfdanarson TR; Johnson DR; Sonbol MB; Kendi AT
Nucl Med Commun; 2023 Jul; 44(7):663-670. PubMed ID: 37158225
[TBL] [Abstract][Full Text] [Related]
26. First-in-Humans Study of the SSTR Antagonist
Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
[TBL] [Abstract][Full Text] [Related]
27. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice.
Soto-Montenegro ML; Peña-Zalbidea S; Mateos-Pérez JM; Oteo M; Romero E; Morcillo MÁ; Desco M
PLoS One; 2014; 9(11):e111624. PubMed ID: 25369268
[TBL] [Abstract][Full Text] [Related]
28. Intraarterial Administration Boosts
Vonken EPA; Bruijnen RCG; Snijders TJ; Seute T; Lam MGEH; Keizer B; Braat AJAT
J Nucl Med; 2022 Mar; 63(3):406-409. PubMed ID: 34301783
[TBL] [Abstract][Full Text] [Related]
29. Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma.
Müther M; Roll W; Brokinkel B; Zinnhardt B; Sporns PB; Seifert R; Schäfers M; Weckesser M; Stegger L; Stummer W; Rahbar K
Nuklearmedizin; 2020 Sep; 59(5):348-355. PubMed ID: 32691404
[TBL] [Abstract][Full Text] [Related]
30. Multimodal Imaging of 2-Cycle PRRT with
Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
[TBL] [Abstract][Full Text] [Related]
31. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
32. Inflammation-Based Index and
Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
[TBL] [Abstract][Full Text] [Related]
33. PRRT with Lu-177 DOTATATE in Treatment-Refractory Progressive Meningioma: Initial Experience from a Tertiary-Care Neuro-Oncology Center.
Puranik AD; Dev ID; Rangarajan V; Kulkarni S; Shetty N; Gala K; Sahu A; Bhattacharya K; Dasgupta A; Chatterjee A; Gupta T; Sridhar E; Sahay A; Shetty P; Singh V; Moiyadi A; Menon N; Purandare NC; Agrawal A; Shah S; Choudhury S; Ghosh S; Jha AK
Neurol India; 2024 Mar; 72(2):278-284. PubMed ID: 38691470
[TBL] [Abstract][Full Text] [Related]
34. The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy.
Lütgendorf-Caucig C; Pelak M; Flechl B; Georg P; Fossati P; Stock M; Traub-Weidinger T; Marosi C; Haberler C; Zechmeister-Machhart G; Hermsmeyer L; Hug E; Staudenherz A
Strahlenther Onkol; 2023 Apr; 199(4):396-403. PubMed ID: 36260109
[TBL] [Abstract][Full Text] [Related]
35. Parametric Net Influx Rate Images of
Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
[No Abstract] [Full Text] [Related]
36. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE; Zhernosekov K
Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
[TBL] [Abstract][Full Text] [Related]
37. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
38. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
[TBL] [Abstract][Full Text] [Related]
39. Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from
Weber M; Kessler L; Schaarschmidt B; Fendler WP; Lahner H; Antoch G; Umutlu L; Herrmann K; Rischpler C
BMC Cancer; 2020 Apr; 20(1):326. PubMed ID: 32299391
[TBL] [Abstract][Full Text] [Related]
40. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
